Therapy of allergic bronchial asthma with omalizumab - an anti-IgE monoclonal antibody

被引:17
作者
D'Amato, G [1 ]
机构
[1] High Specialty Hosp A Cardarelli, Div Pneumol & Allergol, Naples, Italy
关键词
allergic asthma; allergic respiratory diseases; allergy treatment with anti-IgE; anti-IgE antibodies; bronchial asthma; omalizumab; respiratory allergy;
D O I
10.1517/14712598.3.2.371
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The immunoglobulin E (IgE) antibody plays a central role in the allergic immune responses, such as those which characterise allergic bronchial asthma. The ability to reduce circulating IgE by using anti-IgE antibodies represents a novel therapeutic approach for IgE-mediated allergic diseases. Omalizumab (rhuMAb-E25/Xolair(TM); Genentech, USA/Tanox, Inc., USA/Novartis Pharma AG, Switzerland) is a non-anaphylactogen humanised murine monoclonal antibody which binds to circulating IgE. Therapeutic use of an anti-IgE antibody in the treatment of asthma was first suggested in preliminary studies in which omalizumab demonstrated efficacy in attenuating both the early- and late-phase bronchial responses to inhaled allergens in atopic subjects. Treatment with omalizumab has demonstrated both a significant beneficial effect on a number of measures, and a favourable safety profile. It reduces the frequency of asthma exacerbations and the need for inhaled corticosteroids (ICSs), and improves asthma symptoms, lung function and quality of life. The anti-IgE approach to asthma treatment has a number of further potential advantages, such as the treatment of other concomitant atopic diseases (allergic conjunctivitis and rhinitis, atopic dermatitis and food allergy), regardless of the type of allergic sensitisation (seasonal or perennial). On the basis of several studies, omalizumab is likely to provide a new strategy for treating atopic asthma.
引用
收藏
页码:371 / 376
页数:6
相关论文
共 29 条
[1]   Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis [J].
Ädelroth, E ;
Rak, S ;
Haahtela, T ;
Aasand, G ;
Rosenhall, L ;
Zetterstrom, O ;
Byrne, A ;
Champain, K ;
Thirlwell, J ;
Della Cioppa, G ;
Sandström, T .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2000, 106 (02) :253-259
[2]   Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema:: ISAAC [J].
Beasley, R ;
Keil, U ;
von Mutius, E ;
Pearce, N ;
Aït-Khaled, N ;
Anabwani, G ;
Anderson, HR ;
Asher, MI ;
Björkstéin, B ;
Burr, ML ;
Clayton, TO ;
Crane, J ;
Ellwood, P ;
Lai, CKW ;
Mallol, J ;
Martinez, FD ;
Mitchell, EA ;
Montefort, S ;
Robertson, CF ;
Shah, JR ;
Sibbald, B ;
Stewart, AW ;
Strachan, DP ;
Weiland, SK ;
Williams, HC .
LANCET, 1998, 351 (9111) :1225-1232
[3]   Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response [J].
Boulet, LP ;
Chapman, KR ;
Cote, J ;
Kalra, S ;
Bhagat, R ;
Swystun, VA ;
Laviolette, M ;
Cleland, LD ;
Deschesnes, F ;
Su, JQ ;
DeVault, A ;
Fick, RB ;
Cockcroft, DW .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 155 (06) :1835-1840
[4]   EOSINOPHILIC INFLAMMATION IN ASTHMA [J].
BOUSQUET, J ;
CHANEZ, P ;
LACOSTE, JY ;
BARNEON, G ;
GHAVANIAN, N ;
ENANDER, I ;
VENGE, P ;
AHLSTEDT, S ;
SIMONYLAFONTAINE, J ;
GODARD, P ;
MICHEL, FB .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (15) :1033-1039
[5]   The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma [J].
Buhl, R ;
Hanf, G ;
Solèr, M ;
Bensch, G ;
Wolfe, J ;
Everhard, F ;
Champain, K ;
Fox, H ;
Thirlwell, J .
EUROPEAN RESPIRATORY JOURNAL, 2002, 20 (05) :1088-1094
[6]   Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma [J].
Buhl, R ;
Solèr, M ;
Matz, J ;
Townley, R ;
O'Brien, J ;
Noga, O ;
Champain, K ;
Fox, H ;
Thirlwell, J ;
Della Cioppa, G .
EUROPEAN RESPIRATORY JOURNAL, 2002, 20 (01) :73-78
[7]  
Burney P, 1996, EUR RESPIR J, V9, P687
[8]   Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma [J].
Busse, W ;
Corren, J ;
Lanier, BQ ;
McAlary, M ;
Fowler-Taylor, A ;
Della Cioppa, G ;
van As, A ;
Gupta, N .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 108 (02) :184-190
[9]   MECHANISMS OF PERSISTENT AIRWAY INFLAMMATION IN ASTHMA - A ROLE FOR T-CELLS AND T-CELL PRODUCTS [J].
BUSSE, WW ;
COFFMAN, RL ;
GELFAND, EW ;
KAY, AB ;
ROSENWASSER, LJ .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 152 (01) :388-393
[10]  
Casale T, 1999, ANN ALLERG ASTHMA IM, V82, P75